Interaction between $\alpha$-Synuclein and Other Proteins in Neurodegenerative Disorders

Kurt A. Jellinger

Institute of Clinical Neurobiology, Kenyongasse 18, A-1070 Vienna, Austria

Received 30 August 2011; Accepted 10 October 2011

Academic Editors: O. Katsuse, R. Perneczky, D. R. Thal, and Y. Yoshiyama

Protein aggregation is a common characteristic of many neurodegenerative disorders, and the interaction between pathological/toxic proteins to cause neurodegeneration is a hot topic of current neuroscience research. Despite clinical, genetic, and experimental differences, evidence increasingly indicates considerable overlap between synucleinopathies and tauopathies or other protein-misfolding diseases. Inclusions, characteristics of these disorders, also occurring in other neurodegenerative diseases, suggest interactions of pathological proteins engaging common downstream pathways. Novel findings that have shifted our understanding in the role of pathologic proteins in the pathogenesis of Parkinson and Alzheimer diseases have confirmed correlations/overlaps between these and other neurodegenerative disorders. The synergistic effects of $\alpha$-synuclein, hyperphosphorylated tau, amyloid-$\beta$, and other pathologic proteins, and the underlying molecular pathogenic mechanisms, including induction and spread of protein aggregates, are critically reviewed, suggesting a dualism or triad of neurodegeneration in protein-misfolding disorders, although the etiology of most of these processes is still mysterious.

KEYWORDS: neurodegeneration, alzheimer disease, parkinson disease, protein interaction, coformer seeding, pathogenesis
1. INTRODUCTION

Neurodegenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD), frontotemporal degeneration, prion, Huntington, and motoneuron diseases are increasingly being realized to have common cellular and molecular mechanisms including protein aggregation and inclusion body formation in selected areas of the nervous system. Therefore, these disorders are summarized as “proteinopathies” [1, 2]. The aggregations usually consist of insoluble fibrillary aggregates containing misfolded protein with β-sheet formation. The most probable explanation is that these inclusions and aggregates symbolize an end stage of a molecular cascade of complicated events, and that an earlier stage may be more directly tied up to the—hitherto unknown—pathogenesis of the disorder than the inclusions themselves, which may or may not represent diagnostic hallmarks. Small intermediates termed as “soluble oligomers” in the aggregation process may influence synaptic dysfunction, while large insoluble deposits might function as reservoirs of the bioactive oligomers that can lead to synaptic dysfunction, neuronal apoptosis, and brain damage [3, 4]. This is predominantly due to iron-related oxidative damage mediated by α-synuclein (αSyn) oligomerisation during the development of PD pathology [5]. Seeding induced by αSyn oligomers, the toxicity of which has been demonstrated in vivo [6], can induce intracellular αSyn aggregation, providing evidence for spreading of αSyn pathology [7] similar to that of prions [8]. Amyloid-β (Aβ) induces the neurodegenerative triad of spine loss, dendritic changes, and neuritic dystrophies through calcineurin activation [9], while soluble tau species rather than aggregated ones induce neurodegeneration [10]. Tau phosphorylation proceeds to tau aggregation that is favored by kinases like glucose-synthase kinase-3β (GSK-3β) [11], while inhibition of GSK-3β activity prevented not only tau phosphorylation but also tau aggregation in hippocampus [12]. Recent studies showed that caspase activation, observed in a tg mouse model overexpressing GSK-3β [13], precedes tangle formation [14]. Seeding of normal tau by pathological tau conformers further drives pathogenesis of neurofibrillary tangles (NFT) [15]. However, the mechanism by which oligomers trigger neurodegeneration still remains elusive. The aim of this paper is to review the molecular mechanisms and interactions between the various pathological proteins in neurodegeneration.

2. INTERACTION BETWEEN αSyn, Tau, AND AMYLOID-β IN PARKINSON DISEASE

Intracytoplasmic proteinaceous inclusions, primarily composed of tau and/or αSyn, are predominant pathological features of AD and PD, respectively [16]. However, the coexistence of these and other pathological proteinaceous aggregates like Aβ is identified in many neurodegenerative disorders [17–19]. The cooccurrence of both αSyn and tau or other pathologic proteins highlights the interface between them [20]. They may be coaggregated in the same brain or even in the same region or in the same cell in human brains [18, 21, 22] and transgenic mice [23]. Whereas αSyn can spontaneously polymerize into amyloidogenic fibrils, in vitro, tau polymerization requires an inducing agent [24]. Cellular models, various transgenic and other experimental PD models, provided novel insights into the role of αSyn in the hyperphosphorylation of tau protein observed in disease [24–32]. These data suggest that oxidatively modified αSyn is degraded by the proteasome and plays a proaggregatory role for tau [31], and that αSyn is an in vivo regulator of tau protein phosphorylation at Ser (262). Toxic interactions with αSyn may lead to hyperphosphorylation of tau and eventually to the deposition of both proteins in the disease [33]. E46K human αSyn tg mice develop Lewy-like and tau pathology associated with age-dependent motor impairments, supporting the notion that αSyn is involved in the pathogenesis of human diseases [34].

Recent postmortem studies showed increased accumulation of tau protein phosphorylated at Ser 262 and 396/404 in the striata of PD patients and in the A53T αSyn mutant mouse model of PD [27, 35]. This is related to increased activity of GSK-3β [26, 29], a major kinase that hyperphosphorylates tau to produce pathologic forms of tau [36] and may be a possible link between Aβ and tau [37, 38]. Dopamine D1 receptor activation induces tau phosphorylation via cyclin-dependent kinase 5 (cdk5) and GSK-3β.
signaling pathways [39]. Expression of both GSK-3β and microtubule-associated protein/microtubule affinity-regulating kinase 2 inhibited the formation of αSyn-induced tau aggregation [24]. Reduced 19S and 20S proteasomal subunit activities in PD striata suggest that they account for the abnormal disposal of αSyn and phosphorylated tau (p-tau). The small decrease in proteasomal activity in PD striata is consistent with other studies that showed no significant changes of these proteins in PD striata but lower activity in substantia nigra (SN) [40]. In an MPTP model and in MPP+ cellular models, αSyn has been shown to induce GSK-3β-catalyzed tau phosphorylation [41–43]. PD-associated risk factors such as environmental toxins and αSyn mutations promote tau phosphorylation at Ser 262, causing microtubule instability, which leads to neuronal degeneration [30]. Rotenone exposure may also induce αSyn and Aβ aggregation as well as increased hyperphosphorylation of tau, although high concentrations of the pesticide lead to cell death before protein aggregation [32].

Tau in MPTP models and in human postmortem PD striata is hyperphosphorylated at the same sites (Ser 202, 262, and 396/404) as in AD [35], whereas phosphorylation of soluble tau differs in AD and Pick disease brains [44]. Tauopathy in PD striata is restricted to dopaminergic neurons, whereas degeneration in the inferior frontal cortex, associated with increased tau deposition because of diminished proteasomal activity in the absence of oxidative stress and pGSK-3β activity, is not associated with tauopathy [35]. In the αSyn overexpressing mouse model of PD tauopathy, along with microtubule destabilization, exists primarily in the brainstem and striatum, the two major brain regions known to express high levels of αSyn and undergo the highest levels of degeneration in human PD. Thus, tauopathy in PD may have a restricted pattern of distribution [28], which differs from its generalized affection in AD. Whether there are differences in the 3- and 4-repeat tau pathology between these disorders is not yet fully understood and needs further investigation.

There is strong interaction between αSyn, tau, and Aβ, particularly in their oligomeric forms, which might synergistically promote their mutual aggregation and vice versa [33, 45, 46]. Cross-seeding between dissimilar proteins that share β-sheet structures has been described, for example, of Aβ and αSyn [47], tau and αSyn [48], and prion protein and Aβ [49]. In vivo interactions between αSyn and tau are supported by genetic studies [50, 51], and in familial PD, fibrillation of αSyn and tau is caused by the A 53T mutation [48]. A family with early onset dementia was pathologically characterized by widespread appearance of LBs and NFTs, but no amyloid deposits [52]. Recent studies gave evidence that prions trigger hyperphosphorylation of tau in genetic, sporadic, and transmitted forms of prion diseases in the absence of amyloid plaques [53].

Neurofibrillary tau pathology is modulated by genetic variations of αSyn [54]. Tau phosphorylation is found in synapse-enriched fractions of frontal cortex in PD and AD [55] and in brainstems of αSyn mice [56]. Other links between αSyn and tau are suggested by the colocalization of both proteins in both NFTs and Lewy bodies (LBs), especially in neuronal populations vulnerable for both aggregates [21, 57–59], in the olfactory bulb in AD with amygdaloid LBs [57], and in neuronal and glial cytoplasmic inclusions in multiple system atrophy (MSA) [60, 61]. Between 15 and 60% of AD brains show numerous αSyn lesions in the amygdala, even in the absence of subcortical LBs [62, 63]. AD with amygdaloid LBs is considered a distinct form of α-synucleinopathy [64]. In AD patients with clinical extrapyramidal symptoms, between 50 and 88% of the patients showed extensive αSyn pathology co-localized with p-tau in SN, tau and less αSyn pathology in brainstem significantly increasing with higher neuritic Braak stages [65–67].

In conclusion, genetic, pathologic, and biochemical evidence support a role for tau in the pathogenesis of PD [33], and concurrence of tau, αSyn, and TDP-43 pathology in brains of AD and LB disease provide a better understanding of the pathogenic pathways in these disorders [17]. It has been suggested that the process of LB formation is triggered, at least in part, by Alzheimer pathology [18, 68], while the interaction between αSyn and tau in MSA awaits further elucidation [61, 69]. Recent data suggest that PD and AD could be linked by progressive accumulation of p-tau, activated GSK-3β, and αSyn [27, 35, 70, 71], while activation of caspase and caspase-cleft Δtau may represent a common way of abnormal intracellular accumulation of both tau and αSyn, promoted by Aβ deposition, unifying the pathology of AD and LB diseases.
FIGURE 1: Hypothetic diagram unifying pathologic processes in Alzheimer and Lewy body diseases. PD: Parkinson disease; LBD: Lewy body disease; LBs: Lewy bodies; AD: Alzheimer disease.

FIGURE 2: Morphologic interrelations of synucleinopathies, tauopathies, and amyloidopathies. NFTs: neurofibrillary tangles; PSP: progressive supranuclear palsy; CBD: corticofrontal degeneration; PDD: Parkinson disease dementia; DLB: dementia with Lewy bodies; AD: Alzheimer disease; LBs: Lewy bodies.

[72–74] (see Figure 1). In addition, emerging evidence suggests that prion-like spreading, evolving secreted proteins such as Aβ, and cytosolic proteins such as tau and αSyn are spreading by cell-to-cell transmission, thus unifying the pathogenesis of many neurodegenerative disorders [8, 75], but is not fully understood whether they are due to similar protein aggregation and misfolding mechanisms. Combined determination of αSyn, tau, and Aβ concentrations in cerebrospinal fluid (CSF) show differential patterns in these neurodegenerative disorders [76]; in particular tau/αSyn ratios can contribute to the discrimination of PD [77].

Other studies have suggested that Aβ is more likely to promote the deposition of αSyn than tau [78], and Aβ is known to initiate hyperphosphorylation of tau [79]. Cortical αSyn load is associated with Aβ plaque burden in a subset of PD patients [80]. Aβ peptides enhance αSyn accumulation and neuronal deficits in a tg mouse model [81], and αSyn-induced synapse damage is enhanced by Aβ 1-42 [82]. Both can be linked by separate mechanisms driven by a common upstream component [83]. Recent studies showed that Aβ 1-42 tightly binds to tubulin polymerization promoting protein (TPPP/p25) and causes aberrant protein aggregations inhibiting the physiologically relevant TPPP/p25-derived microtubule assembly, the interaction of TPPP/p25 and Aβ can produce pathologic aggregates in AD and LB diseases [84]. These lesions represent a collision of two or more processes, but it is unclear whether there is a common underlying final pathology leading to neuronal degeneration (see [85]) (Figure 2).
3. AMYLOID-β AND Tau IN ALZHEIMER DISEASE

The brains in patients with AD, in addition to nerve and synapse loss, are characterized by two hallmark lesions, Aβ-containing plaques and NFT, which are composed of hyperphosphorylated forms of microtubule-associated protein tau [86]. Progression of NFT pathology throughout the brain correlates with disease progression [87], and loss of synapses is one of the earliest events that has been associated with functional impairment [88]. Although both Aβ and tau have been extensively studied with regard to their separate modes of toxicity (see [89]), more recently new light has been shed on their possible interactions and synergistic effects in AD, linking Aβ and tau [90, 91]. Moreover, the interaction between tau and Aβ mediated by FIN kinase should be considered, since it is an interesting link between the two pathogenic hallmarks of the disorders [36–38].

According to the amyloid cascade hypothesis, Aβ formation is the critical step in diving AD’s pathogenesis [92]. Support for this concept stems from the identification of pathogenic mutations in patients with familial AD linked to Aβ formation and a higher frequency of AD in people with trisomy 21, who carry an additional APP allele [93].

Although Aβ and tau exert toxicity through separate mechanisms [94], evidence from both in vitro and in vivo models suggest that there are three possible models of interaction between the two. (1) Aβ drives tau pathology, supported by induction of tau hyperphosphorylation by Aβ formation in APP tg mice [95], induction of neuronal tau hyperphosphorylation by Aβ oligomers [96] and, together with neuritic degeneration, by soluble Aβ-protein dimers isolated from Alzheimer cortex [97], or by Aβ-rich brain extracts [98], and aggravation of NFT pathology by intracranial injection of synthetic Aβ into mutant tau tg mice [99]. On the other hand, a single-dose intraventricular injection of an Aβ antibody in 4-month-old mice cleared intraneuronal Aβ pathology and reduced early cognitive deficits [100], and inhibition of GSK-3β attenuated Aβ-induced tau phosphorylation in vitro and can reduce tau pathology in vivo [12, 101]. Other data suggest induction of NFT formation by amyloidogenic peptides rather than specifically by Aβ [102]. While the 3xtg AD mouse model, based on early intraneuronal accumulation of Aβ played an important role in supporting the “intraneuronal Aβ hypothesis” [100], recent evidence claims that these mice early and age-dependently accumulate AβPP instead of Aβ within neurons [103, 104], thus challenging this hypothesis. (2) Synergistic effects of Aβ and tau by impairment of mitochondrial respiration in triple tg mice that display both Aβ and tau pathologies [105]. This indicates the convergence of Aβ and tau on mitochondrial deterioration and establishes a molecular link in AD pathology in vivo [106, 107]. (3) Tau mediates Aβ toxicity supported by the observation that tau −/− neurons are protected from Aβ induced cell death in cell culture [108–110]. Tau reduction also prevents Aβ-induced defects in axonal transport of mitochondria and other cargoes [111], which may link the “tau hypothesis” to other ones, the axonal transport impairment hypothesis, according to which tau induces failure of axonal transport [112, 113], and the “oxidative stress hypothesis” according to which mitochondria are functionally impaired, resulting in the production of reactive oxidative species [114]. Astrocytes have been shown to be important mediators of Aβ-induced neurotoxicity and tau hyperphosphorylation in primary cultures [13].

Although knowledge about the roles of tau and its interactions with Aβ is increasing (see [1, 115]), many questions about the scaffolding partners for tau in its interaction with Aβ are still unanswered. While this phenomenon may result from direct cross-seeding of tau by aggregated Aβ [116, 117], indirect pathways such as Aβ-induced tau phosphorylation, inflammation, and/or disruption of proteostasis [37, 91, 118] have not been ruled out.

As we gain a deeper understanding of the different cellular functions of tau, the focus shifts from the axon, where tau has a principal role as microtubule-associated protein, to the dendrite, where it mediates Aβ toxicity [91]. On the other hand, according to several data, tau aggregates may be a consequence rather than a cause of neurodegeneration [14, 119]. Therefore, the effects promoted by Aβ and tau should be analyzed more specifically to identify the mechanisms that underlay Aβ and tau toxicity and/or neuroprotection in order to find appropriate therapeutic targets.
4. INDUCTION AND SPREAD OF PROTEIN AGGREGATES IN NEURODEGENERATIVE DISEASES

Increasing evidence implicates the importance of disease-specific proteins and their interrelations in various neurodegenerative disorders [1–4, 16]. In PD, αSyn-rich lesions that typify Lewy body pathology, first arise in the lower brainstem and in the anterior olfactory nucleus and olfactory bulb; they subsequently appear in a predictable sequence in mesencephalic and neocortical regions [120–122], although their reliability of Lewy pathology staging in sporadic PD has been a matter of discussion [123–126]. The concept that αSyn lesions ramify within the CNS by a seeding-like process is supported by the observation that fetal dopaminergic transplants in the striatum of a subset of PD patients surviving more than 5 years may develop αSyn-positive Lewy bodies [127–129]. These data imply for a host-to-graft propagation of αSyn, but the effects of LBs in the grafted neurons are unclear [129], although neuron-to-neuron (interneuron) transmission or transsynaptic spread of αSyn appears a likely interpretation for the propagation of the disease [8, 129]. It has been suggested that LBs develop in transplanted dopaminergic neurons in a fashion similar to that in the host SN [130]. On the other hand, LB pathology in grafted neurons does not necessarily mean their functional impairment. Similar accumulation of αSyn occurs in stem cells transplanted into transgenic mice [8]. Secreted αSyn can recruit endogenous αSyn in the recipient cells, act as a permissive template, and promote misfolding in small aggregates [131]. Some of the uptake of αSyn from the extracellular space appears to occur via endocytosis, although additional mechanisms might also contribute [131, 132]. It is probable to trigger the formation of large LB-like aggregates in cultured cells, when artificial methods, bypassing physiologic uptake mechanisms, are used to promote the entry of misfolded αSyn. In vivo approaches in cell cultures could not discriminate between a prion-like mechanism—host-derived, misfolded αSyn inducing misfolding of αSyn generated in the graft—versus simple translocation of aggregated synuclein from the host to the graft. Thus, in cell culture all the mechanisms needed for prion-like behavior of misfolded αSyn appear to be in place [131, 133, 134]. These and other data suggest that αSyn pathology could be induced in cells and may spread by a prion-like mechanism involving the transmission of conformationally altered αSyn [135–138]. Thus, the prion-like propagation of αSyn lesions has been demonstrated as has the induction of proteinaceous lesions associated with other neurodegenerative diseases, such as aggregates of superoxide dismutase 1 (SOD1) [139, 140], aggregates of polyamine [141], which typify Huntington disease and spinocerebellar ataxias, or cytosolic aggregates of TDP-43 [142], which are present in ALS and frontotemporal lobar degeneration with TDP-43-positive inclusions (FTDL-TDP). The capability of passing between living cells is not limited to prions and those cited above; it was also shown for aggregates of truncated tau, consisting of the microtubule-binding region and a fluorescent protein tag that can leave and enter cells in culture and promote the aggregates and fibrillation of normal tau within them [115, 143–146]. The recent demonstration of tau-positive pretangle material in the locus ceruleus before involvement of the transentorhinal region of the cerebral cortex in young individuals [147] suggests a progression of tau pathology via neuron-to-neuron transmission and transsynaptic transport of tau protein aggregates [148], since seeding of neuronal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles [15]. These data may indicate that the currently used neuropathological stages of AD [149–151] will have to be reclassified. Mutant P201S tau, as found in frontotemporal dementia with parkinsonism (FDTPL-19), is capable of spreading through the cortex of an Alz 17 tg mouse expressing the human wild-type protein and induce an NFT-like pathology that consists of human tau in brain areas distant from the injection site [145]. These and other data raise the possibility that neurodegenerative pathologies could spread within the brain via a mechanism analogous to prion-like self-propagation, although alternative mechanisms, such as disruption of basic cellular proteostasis by exogenous aggregates, cannot be excluded [152]. Furthermore, tau and αSyn are present in blood and CSF in both monomeric and oligomeric forms, suggesting release of these normally intracellular proteins in vivo [77, 153–155]. The intercellular transfer of cytosolic protein aggregates may also occur through nanotubes, exosomes, or microvesicles [135]. Like other pathogenic proteins, Aβ can be taken up, modified, and secreted by cells in vitro [108, 156], and it is also present in the CSF [157].
5. CONCLUSIONS

Interaction between \( \alpha \)Syn, tau, and A\( \beta \) may be a molecular mechanism in the overlapping pathology of LB disease and AD, possibly representing a complex continuum, characterized by variable amounts of pathologic proteins, and A\( \beta \) is suggested to promote accumulation of both \( \alpha \)Syn and tau; the procession from A\( \beta \) to neurite pathology in the cerebral cortex of AD and DLB may be unifiable [73, 74]. DLB-3xtg-AD mice exhibit accelerated formation of \( \alpha \)Syn and LB-like inclusions in the cortex and enhanced increase of p-tau deposits immunoreactive for antibody AT8 in the hippocampus, and neocortex provide further evidence that tau, \( \alpha \)Syn, and A\( \beta \) interact in vivo to promote accumulation of each other and accelerate cognitive dysfunction, although accumulation of \( \alpha \)Syn alone can significantly disrupt cognition [158, 159]. Polymorphic tau and A\( \beta \)-tau aggregates may be due to repeated sequences, which are prone to variable turn locations along the tau repeats, suggesting that synergistic interactions between repeats in tau protein and A\( \beta \) may be responsible for accelerated aggregation via polymorphic states [117]. These changes and common inflammatory mechanisms in these disorders [160] could be generated by the same stimulus, with the outcome possibly having an inverse relationship depending on genetic backgrounds and environmental factors. Although recent data documented colocalization of \( \alpha \)Syn and tau in LBs [57], of A\( \beta \) and p-tau in synaptosomes [161], synaptic terminals [162], and in triple transgenic mice [105], why tau, A\( \beta \), and \( \alpha \)Syn pathologies are so intimately associated remains one of the major questions of the pathogenesis of neurodegeneration in selected/vulnerable brain regions that are typical for different disease processes (double or triple amyloidoses). It has been suggested that these pathologies represent a common final pathway leading to or preventing neuronal damage [23, 70, 71, 85]. The basic molecular mechanisms (presumed regional differences in proteasomal, caspase, GSK-3\( \beta \) activities, oxidative stress in the presence of \( \alpha \)Syn deposition, etc.) need further elucidation, and the molecular basis of the synergistic effects of \( \alpha \)Syn, p-tau, A\( \beta \), and other pathologic proteins, suggesting a dualism or triad of neurodegeneration, are a major challenge for modern neuroscience. Improved understanding of these mechanisms may not only improve our insight into the pathogenesis of proteinopathies, but also have an impact on diagnostic and therapeutic possibilities.

REFERENCES

[1] M. Jucker and L. C. Walker, “Pathogenic protein seeding in Alzheimer’s disease and other neurodegenerative disorders,” Annals of Neurology. In press.
[2] T. E. Golde and V. M. Miller, “Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer’s and other neurodegenerative diseases,” Alzheimer’s Research & Therapy, vol. 1, no. 2, article 5, 2009.
[3] B. S. Gadad, G. B. Britton, and K. S. Rao, “Targeting oligomers in neurodegenerative disorders: lessons from \( \alpha \)-synuclein, tau, and amyloid-\( \beta \) peptide,” Journal of Alzheimer’s Disease, vol. 24, supplement 2, pp. 223–232, 2011.
[4] K. R. Patterson, C. Remmers, Y. Fu et al., “Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease,” The Journal of Biological Chemistry, vol. 286, no. 26, pp. 23063–23076, 2011.
[5] D. Olivares, X. Huang, L. Branden, N. H. Greig, and J. T. Rogers, “Physiological and pathological role of alpha-synuclein in parkinson’s disease through iron mediated oxidative stress; the role of a putative iron-responsive element,” International Journal of Molecular Sciences, vol. 10, no. 3, pp. 1226–1260, 2009.
[6] B. Winner, R. Jappelli, S. K. Maji et al., “In vivo demonstration that \( \alpha \)-synuclein oligomers are toxic,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 10, pp. 4194–4199, 2011.
[7] K. M. Danzer, S. K. Krebs, M. Wolff, G. Birk, and B. Hengerer, “Seeding induced by \( \alpha \)-synuclein oligomers provides evidence for spreading of \( \alpha \)-synuclein pathology,” Journal of Neurochemistry, vol. 111, no. 1, pp. 192–203, 2009.
[8] S. J. Lee, P. Desplats, C. Sigurdson, I. Tsigelny, and E. Masliah, “Cell-to-cell transmission of non-prion protein aggregates,” Nature Reviews Neurology, vol. 6, no. 12, pp. 702–706, 2010.
[9] H. Y. Wu, E. Hudry, T. Hashimoto et al., “Amyloid β induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation,” *Journal of Neuroscience*, vol. 30, no. 7, pp. 2636–2649, 2010.

[10] L. M. Fox, C. M. William, D. H. Adamowicz et al., “Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model,” *Journal of Neuropathology and Experimental Neurology*, vol. 70, no. 7, pp. 588–595, 2011.

[11] W. Noble, E. Planel, C. Zehr et al., “Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 19, pp. 6990–6995, 2005.

[12] T. Engel, P. Goñi-Oliver, J. J. Lucas, J. Avila, and F. Hernández, “Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert,” *Journal of Neurochemistry*, vol. 99, no. 6, pp. 1445–1455, 2006.

[13] J. J. Lucas, F. Hernández, P. Gómez-Ramos, M. A. Morán, R. Hen, and J. Avila, “Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice,” *The EMBO Journal*, vol. 20, no. 1-2, pp. 27–39, 2001.

[14] A. de Calignon, L. M. Fox, R. Pitstick et al., “Caspase activation precedes and leads to tangles,” *Nature*, vol. 464, no. 7292, pp. 1201–1204, 2010.

[15] J. L. Guo and V. M.-Y. Lee, “Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles,” *The Journal of Biological Chemistry*, vol. 286, no. 17, pp. 15317–15331, 2011.

[16] G. B. Irvine, O. M. El-Agnaf, G. M. Shankar, and D. M. Walsh, “Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases,” *Molecular Medicine*, vol. 14, no. 7-8, pp. 451–464, 2008.

[17] S. Higashi, E. Iseki, R. Yamamoto et al., “Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies,” *Brain Research*, vol. 1184, no. 1, pp. 284–294, 2007.

[18] E. Iseki, T. Togo, K. Suzuki et al., “Dementia with Lewy bodies from the perspective of tauopathy,” *Acta Neuropathologica*, vol. 105, no. 3, pp. 265–270, 2003.

[19] J. Miklossy, J. C. Steele, S. Yu et al., “Enduring involvement of tau, β-amyloid, α-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC),” *Acta Neuropathologica*, vol. 116, no. 6, pp. 625–637, 2008.

[20] W. R. Galpern and A. E. Lang, “Interface between tauopathies and synucleinopathies: a tale of two proteins,” *Annals of Neurology*, vol. 59, no. 3, pp. 449–458, 2006.

[21] Y. Arai, M. Yamazaki, O. Mori, H. Muramatsu, G. Asano, and Y. Katayama, “α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation,” *Brain Research*, vol. 888, no. 2, pp. 287–296, 2001.

[22] J. E. Duda, B. I. Giasson, M. E. Mabon et al., “Concurrence of α-synuclein and tau brain pathology in the Contursi kindred,” *Acta Neuropathologica*, vol. 104, no. 1, pp. 7–11, 2002.

[23] E. Maries, B. Dass, T. J. Collier, J. H. Kordower, and K. Steece-Collier, “The role of α-synuclein in Parkinson’s disease: insights from animal models,” *Nature Reviews Neuroscience*, vol. 4, no. 9, pp. 727–738, 2003.

[24] E. A. Waxman and B. I. Giasson, “Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau,” *Journal of Neuroscience*, vol. 31, no. 21, pp. 7604–7618, 2011.

[25] T. Nonaka, S. T. Watanabe, T. Iwatsubo, and M. Hasegawa, “Seeded aggregation and toxicity of α-synuclein and tau: cellular models of neurodegenerative diseases,” *The Journal of Biological Chemistry*, vol. 285, no. 45, pp. 34885–34898, 2010.

[26] T. Duka, V. Duka, J. N. Joyce, and A. Sidhu, “α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson’s disease’s models,” *The FASEB Journal*, vol. 23, no. 9, pp. 2820–2830, 2009.

[27] J. Wills, J. Credle, T. Haggerty, J.-H. Lee, A. W. Oaks, and A. Sidhu, “Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson’s disease,” *PLoS One*, vol. 6, no. 3, Article ID e17953, 2011.

[28] T. Kaul, J. Credle, T. Haggerty, A. W. Oaks, E. Masliah, and A. Sidhu, “Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson’s disease,” *BMC Neuroscience*, vol. 12, article 79, 2011.
[29] T. Haggerty, J. Credle, O. Rodriguez et al., “Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson’s disease,” European Journal of Neuroscience, vol. 33, no. 9, pp. 1598–1610, 2011.

[30] H. Y. Qureshi and H. K. Paudel, “Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and α-synuclein mutations promote tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro,” The Journal of Biological Chemistry, vol. 286, no. 7, pp. 5055–5068, 2011.

[31] M. Riedel, O. Goldbaum, and C. Richter-Landsberg, “α-Synuclein promotes the recruitment of tau to pro-tein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress,” Journal of Molecular Neuroscience, vol. 39, no. 1-2, pp. 226–234, 2009.

[32] R. S. Chaves, T. Q. Melo, S. A. Martins, and M. F. R. Ferrari, “Protein aggregation containing beta-amyloid, alpha-synuclein and hyperphosphorylated tau in cultured cells of hippocampus, substantia nigra and locus coeruleus after rotenone exposure,” BMC Neuroscience, vol. 11, article 144, 2010.

[33] P. Lei, S. Ayton, D. I. Finkelstein, P. A. Adlard, C. L. Masters, and A. I. Bush, “Tau protein: relevance to Parkinson’s disease,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 11, pp. 1775–1778, 2010.

[34] K. L. Emmer, E. A. Waxman, J. P. Covy, and B. I. Giasson, “E46K human α-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment,” The Journal of Biological Chemistry, vol. 286, no. 40, pp. 35104–35118, 2011.

[35] J. Wills, J. Jones, T. Haggerty, V. Duka, J. N. Joyce, and A. Sidhu, “Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia,” Experimental Neurology, vol. 225, no. 1, pp. 210–218, 2010.

[36] L. Baum, R. Seger, J. R. Woodgett et al., “Overexpressed tau protein in cultured cells is phosphorylated without formation of PHF: implication of phosphoprotein phosphatase involvement,” Molecular Brain Research, vol. 34, no. 1, pp. 1–17, 1995.

[37] F. Hernández, E. Gómez de Barreda, A. Fuster-Matanzo, J. J. Lucas, and J. Avila, “GSK3: a possible link between beta amyloid peptide and tau protein,” Experimental Neurobiology, vol. 223, no. 2, pp. 322–325, 2010.

[38] C. Hooper, R. Killick, and S. Lovestone, “The GSK3 hypothesis of Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 104, no. 6, pp. 1433–1439, 2008.

[39] M. Lebel, C. Patenaude, J. Allyson, G. Massicotte, and M. Cy, “Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways,” Neuropharmacology, vol. 57, no. 4, pp. 392–402, 2009.

[40] K. S. P. McNaught, R. Belizaire, P. Jenner, C. W. Olanow, and O. Isacson, “Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson’s disease,” Neuroscience Letters, vol. 326, no. 3, pp. 155–158, 2002.

[41] T. Duka, M. Rusnak, R. E. Drolet et al., “Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism,” The FASEB Journal, vol. 20, no. 13, pp. 2302–2312, 2006.

[42] T. Duka and A. Sidhu, “The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of α-Synuclein, in SH-SY5Y neuroblastoma cells,” Neurotoxicity Research, vol. 10, no. 1, pp. 1–10, 2006.

[43] A. P. Kozikowski, I. N. Gaisina, P. A. Petukhov et al., “Highly potent and specific GSK-3β inhibitors that block tau phosphorylation and decrease α-synuclein protein expression in a cellular model of Parkinson’s disease,” ChemMedChem, vol. 1, no. 2, pp. 256–266, 2006.

[44] J. van Eersel, M. Bi, Y. D. Ke et al., “Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains,” Journal of Neural Transmission, vol. 116, no. 10, pp. 1243–1251, 2009.

[45] B. I. Giasson, M. S. Forman, M. Higuchi et al., “Initiation and synergistic fibrillization of tau and alpha-synuclein,” Science, vol. 300, no. 5619, pp. 636–640, 2003.

[46] V. N. Uversky, “Neuropathology, biochemistry, and biophysics of α-synuclein aggregation,” Journal of Neurochemistry, vol. 103, no. 1, pp. 17–37, 2007.

[47] I. F. Tsigelny, L. Crews, P. Desplats et al., “Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases,” PLoS One, vol. 3, no. 9, Article ID e3135, 2008.

[48] P. T. Kotzbauer, B. I. Giasson, A. V. Kravitz et al., “Fibrillization of α-synuclein and tau in familial Parkinson’s disease caused by the A53T α-synuclein mutation,” Experimental Neurology, vol. 187, no. 2, pp. 279–288, 2004.

[49] R. Morales, L. D. Estrada, R. Diaz-Espinoza et al., “Molecular cross talk between misfolded proteins in animal models of alzheimer’s and prion diseases,” Journal of Neuroscience, vol. 30, no. 13, pp. 4528–4535, 2010.
[50] C. H. Williams-Gray, J. R. Evans, A. Goris et al., “The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort.” Brain, vol. 132, no. 11, pp. 2958–2969, 2009.
[51] S. Wray and P. A. Lewis, “A tangled web—tau and sporadic Parkinson’s disease,” Front Psychiatry, vol. 1, article 150, 2010.
[52] J. Clarimon, L. Molina-Porcel, T. Gomez-Isla et al., “Early-onset familial lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 1, pp. 73–82, 2009.
[53] L. Reiniger, A. Lukic, J. Linehan et al., “Tau, prions and Aβ: the triad of neurodegeneration,” Acta Neuropathologica, vol. 121, no. 1, pp. 5–20, 2011.
[54] T. Peuralinna, M. Oinas, T. Polvikoski et al., “Neurofibrillary tau pathology modulated by genetic variation of α-synuclein,” Annals of Neurology, vol. 64, no. 3, pp. 348–352, 2008.
[55] G. Muntau, E. Dalfó, A. Martinez, and I. Ferrer, “Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related α-synucleinopathies,” Neuroscience, vol. 152, no. 4, pp. 913–923, 2008.
[56] M. Frasier, M. Walzer, L. McCarthy et al., “Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein,” Experimental Neurology, vol. 192, no. 2, pp. 274–287, 2005.
[57] H. Fujishiro, Y. Tsuboi, W. L. Lin, H. Uchikado, and D. W. Dickson, “Co-localization of tau and α-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies,” Acta Neuropathologica, vol. 116, no. 1, pp. 17–24, 2008.
[58] C. Y. Shao, J. F. Crary, C. Rao, T. C. Sacktor, and S. S. Mirra, “Atypical protein kinase C in neurodegenerative disease II: PKCι/λ in tauopathies and α-synucleinopathies,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 4, pp. 327–335, 2006.
[59] T. Ishizawa, P. Mattila, P. Davies, D. Wang, and D. W. Dickson, “Colocalization of tau and alpha-synuclein epitopes in Lewy bodies,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 4, pp. 389–397, 2003.
[60] Y. S. Piao, S. Hayashi, M. Hasegawa et al., “Co-localization of α-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration,” Acta Neuropathologica, vol. 101, no. 3, pp. 285–293, 2001.
[61] M. Nagaishi, H. Yokoo, and Y. Nakazato, “Tau-positive glial cytoplasmic granules in multiple system atrophy,” Neuropathology, vol. 31, no. 3, pp. 299–305, 2011.
[62] D. W. Dickson, “α-Synuclein and the lewy body disorders,” Current Opinion in Neurology, vol. 14, no. 4, pp. 423–432, 2001.
[63] Y. Trembath, C. Rosenberg, J. F. Ervin et al., “Lewy body pathology is a frequent co-pathology in familial Alzheimer’s disease,” Acta Neuropathologica, vol. 105, no. 5, pp. 484–488, 2003.
[64] H. Uchikado, W.-L. Lin, M. W. Delucia, and D. W. Dickson, “Alzheimer disease with amygdala lewy bodies: a distinct form of α-synucleinopathy,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 7, pp. 685–697, 2006.
[65] J. Attems, M. Quass, and K. A. Jellinger, “Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs,” Acta Neuropathologica, vol. 113, no. 1, pp. 53–62, 2007.
[66] J. M. Burns, J. E. Galvin, C. M. Roe, J. C. Morris, and D. W. McKeel, “The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs,” Neurology, vol. 64, no. 8, pp. 1397–1403, 2005.
[67] Y. Liu, Y. Stern, M. R. Chun, D. M. Jacobs, P. Yau, and J. E. Goldman, “Pathological correlates of extrapyramidal signs in Alzheimer’s disease,” Annals of Neurology, vol. 41, no. 3, pp. 368–374, 1997.
[68] Y. Saito, N. N. Ruberu, M. Sawabe et al., “Lewy body-related α-synucleinopathy in aging,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 7, pp. 742–749, 2004.
[69] K. Jellinger, “Unusual tau in MSA,” Neuropathology. In press.
[70] K. A. Jellinger, “Interaction between alpha-synuclein and tau in Parkinson’s disease Comment on Wills et al.: elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia,” Experimental Neurology, vol. 225, no. 1, pp. 210–218, 2011.
[71] K. A. Jellinger, “Interaction between alpha-synuclein and tau in Parkinson’s disease Comment on Wills et al.: elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia,” Experimental Neurology, vol. 227, no. 1, pp. 13–18, 2011.
[72] V. M. Y. Lee, B. I. Giasson, and J. Q. Trojanowski, “More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases,” *Trends in Neurosciences*, vol. 27, no. 3, pp. 129–134, 2004.

[73] P. K. Mandal, J. W. Petegrew, E. Masliah, R. L. Hamilton, and R. Mandal, “Interaction between Aβ peptide and α-synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease,” *Neurochemical Research*, vol. 31, no. 9, pp. 1153–1162, 2006.

[74] K. Obi, H. Akiyama, H. Kondo et al., “Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies,” *Experimental Neurology*, vol. 210, no. 2, pp. 409–420, 2008.

[75] S.-J. Lee, H.-S. Lim, E. Masliah, and H.-J. Lee, “Protein aggregate spreading in neurodegenerative diseases: problems and perspectives,” *Neuroscience Research*, vol. 70, no. 4, pp. 339–348, 2011.

[76] B. Mollenhauer, J. J. Locascio, W. Schulz-Schaeffer, F. Sixel-Döring, and C. Trenkwalder, “α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study,” *The Lancet Neurology*, vol. 10, no. 3, pp. 230–240, 2011.

[77] L. Parnetti, D. Chiasserini, G. Bellomo et al., “Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias,” *Movement Disorders*, vol. 26, no. 8, pp. 1428–1435, 2011.

[78] O. Pletnikova, N. West, M. K. Lee et al., “Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases,” *Neurobiology of Aging*, vol. 26, no. 8, pp. 1183–1192, 2005.

[79] H. C. Huang and Z. F. Jiang, “Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer’s disease,” *Journal of Alzheimer’s Disease*, vol. 16, no. 1, pp. 15–27, 2009.

[80] T. Lashley, J. L. Holton, E. Gray et al., “Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients,” *Acta Neuropathologica*, vol. 115, no. 4, pp. 417–425, 2008.

[81] E. Masliah, E. Rockenstein, I. Veinbergs et al., “β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 21, pp. 12245–12250, 2001.

[82] C. Bate, S. Gentleman, and A. Williams, “alpha-synuclein induced synapse damage is enhanced by amyloid-beta1-42,” *Molecular Neurodegeneration*, vol. 5, article 55, 2010.

[83] S. A. Small and K. Duff, “Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis,” *Neuron*, vol. 60, no. 4, pp. 534–542, 2008.

[84] J. Oláh, O. Vincze, D. Virók et al., “Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, β-amyloid, and α-synuclein,” *The Journal of Biological Chemistry*, vol. 286, no. 39, pp. 34088–34100, 2011.

[85] K. A. Jellinger, “Basic mechanisms of neurodegeneration: a critical update,” *Journal of Cellular and Molecular Medicine*, vol. 14, no. 3, pp. 457–487, 2010.

[86] H. W. Querfurth and F. M. LaFerla, “Alzheimer’s disease,” *The New England Journal of Medicine*, vol. 362, no. 4, pp. 329–344, 2010.

[87] H. Braak and E. Braak, “Staging of Alzheimer’s disease-related neurofibrillary changes,” *Neurobiology of Aging*, vol. 16, no. 3, pp. 271–278, 1995.

[88] D. J. Selkoe, “Alzheimer’s disease is a synaptic failure,” *Science*, vol. 298, no. 5594, pp. 789–791, 2002.

[89] J. Hardy, “The relationship between amyloid and tau,” *Journal of Molecular Neuroscience*, vol. 20, no. 2, pp. 203–206, 2003.

[90] J. Götz, Y. A. Lim, Y. D. Ke, A. Eckert, and L. M. Ittner, “Dissecting toxicity of tau and β-amyloid,” *Neurodegenerative Diseases*, vol. 7, no. 1–3, pp. 10–12, 2010.

[91] L. M. Ittner and J. Götz, “Amyloid-β and tau—a toxic pas de deux in Alzheimer’s disease,” *Nature Reviews Neuroscience*, vol. 12, pp. 65–72, 2010.

[92] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics,” *Science*, vol. 297, no. 5580, pp. 353–356, 2002.

[93] L. Bertram and R. E. Tanzi, “The genetic epidemiology of neurodegenerative disease,” *The Journal of Clinical Investigation*, vol. 115, no. 6, pp. 1449–1457, 2005.

[94] D. H. Small, S. S. Mok, and J. C. Bornstein, “Alzheimer’s disease and Aβ toxicity: from top to bottom,” *Nature Reviews Neuroscience*, vol. 2, no. 8, pp. 595–598, 2001.
L. Rajendran, M. Honsho, T. R. Zahn et al., “Alzheimer's disease
C. B. Saper, B. H. Wainer, and D. C. German, “Axonal and transneuronal transport in the transmission of
β
K. A. Vossel, K. Zhang, J. Brodbeck et al., “Tau reduction prevents A
A. Eckert and K. Schmitt, “Mitochondrial dysfunction—the beginning of the end in Alzheimer’s disease?
A. Eckert, K. L. Schulz, V. Rhein, and J. Götz, “Convergence of amyloid-β and tau pathologies on mitochondria in vivo,” Molecular Neurobiology, vol. 41, no. 2-3, pp. 107–114, 2010.
L. Rajendran, M. Honsho, T. R. Zahn et al., “Alzheimer’s disease β-amyloid peptides are released in association with exosomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 30, pp. 11172–11177, 2006.
E. D. Roberson, K. Scearce-Levie, J. J. Palop et al., “Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer’s disease mouse model,” Science, vol. 316, no. 5825, pp. 750–754, 2007.
L. M. Ittner, Y. D. Ke, F. Delerue et al., “Dendritic function of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models,” Cell, vol. 142, no. 3, pp. 387–397, 2010.
K. A. Vossel, K. Zhang, J. Brodbeck et al., “Tau reduction prevents Aβ-induced defects in axonal transport,” Science, vol. 330, no. 6001, pp. 198–198, 2010.
C. B. Saper, B. H. Wainer, and D. C. German, “Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer’s disease,” Neuroscience, vol. 23, no. 2, pp. 389–398, 1987.
K. Stamer, R. Vogel, E. Thies, E. Mandelkow, and E. M. Mandelkow, “Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress,” Journal of Cell Biology, vol. 156, no. 6, pp. 1051–1063, 2002.
M. A. Pappolla, R. A. Omar, K. S. Kim, and N. K. Robakis, “Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer’s disease,” American Journal of Pathology, vol. 140, pp. 621–628, 1992.
P. Novak, M. Prcina, and E. Kontsekova, “Tauons and prions: infamous cousins?” Journal of Alzheimer’s Disease, vol. 26, no. 3, pp. 413–430, 2011.
[116] J. P. Guo, T. Arai, J. Miklossy, and P. L. McGeer, “Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer’s disease,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, pp. 1953–1958, 2006.

[117] Y. Miller, B. Ma, and R. Nussinov, “Synergistic interactions between repeats in tau protein and Aβ amyloids may be responsible for accelerated aggregation via polymorphic States,” *Biochemistry*, vol. 50, no. 23, pp. 5172–5181, 2011.

[118] Y. Yoshiyama, M. Higuchi, B. Zhang et al., “Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model,” *Neuron*, vol. 53, no. 3, pp. 337–351, 2006.

[119] J. Avila, “Alzheimer disease: caspases first,” *Nature Reviews Neurology*, vol. 6, no. 11, pp. 587–588, 2010.

[120] H. Braak, K. Del Tredici, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson’s disease,” *Neurobiology of Aging*, vol. 24, no. 2, pp. 197–211, 2003.

[121] H. Braak and K. Del Tredici, “Neuroanatomy and pathology of sporadic Parkinson’s disease,” *Advances in Anatomy, Embryology, and Cell Biology*, vol. 201, pp. 1–119, 2009.

[122] H. Braak and K. Del Tredici, “Pathophysiology of sporadic Parkinson’s disease,” *Fortschritte der Neurologie-Psychiatrie*, vol. 78, supplement 1, pp. S2–S4, 2010.

[123] L. Parkkinen, T. Pirttiiä, and I. Alafuzoff, “Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance,” *Acta Neuropathologica*, vol. 115, no. 4, pp. 399–407, 2008.

[124] M. Kalaitzakis, M. B. Graeber, S. M. Gentleman, and R. K. B. Pearce, “Controversies over the staging of α-synuclein pathology in Parkinson’s disease,” *Acta Neuropathologica*, vol. 116, no. 1, pp. 125–128, 2008.

[125] K. A. Jellinger, “A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders,” *Biochimica et Biophysica Acta*, vol. 1792, no. 7, pp. 730–740, 2009.

[126] D. W. Dickson, H. Uchikado, H. Fujishiro, and Y. Tsuboi, “Evidence in favor of Braak staging of Parkinson’s disease,” *Movement Disorders*, vol. 25, supplement 1, pp. S78–S82, 2010.

[127] J. H. Kordower, Y. Chu, R. A. Hauser, C. W. Olanow, and T. B. Freeman, “Transplanted dopaminergic neurons develop PD pathologic changes: a second case report,” *Movement Disorders*, vol. 23, no. 16, pp. 2303–2306, 2008.

[128] J. Y. Li, E. Englund, J. L. Holton et al., “Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation,” *Nature Medicine*, vol. 14, no. 5, pp. 501–503, 2008.

[129] P. Brundin, J. Y. Li, J. L. Holton, O. Lindvall, and T. Revesz, “Research in motion: the enigma of Parkinson’s disease pathology spread,” *Nature Reviews Neuroscience*, vol. 9, no. 10, pp. 741–745, 2008.

[130] J. Y. Li, E. Englund, H. Widner et al., “Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson’s disease,” *Movement Disorders*, vol. 25, no. 8, pp. 1091–1096, 2010.

[131] C. Hansen, E. Angot, A.-L. Bergström et al., “α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells,” *The Journal of Clinical Investigation*, vol. 121, no. 2, pp. 715–725, 2011.

[132] H.-J. Lee, J.-E. Suk, E.-J. Bae, J.-H. Lee, S. R. Paik, and S.-J. Lee, “Assembly-dependent endocytosis and clearance of extracellular α-synuclein,” *International Journal of Biochemistry and Cell Biology*, vol. 40, no. 9, pp. 1835–1849, 2008.

[133] P. Desplats, H. J. Lee, E. J. Bae et al., “Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 31, pp. 13010–13015, 2009.

[134] J. H. Kordower, H. B. Dodiya, A. M. Kordower et al., “Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat,” *Neurobiology of Disease*, vol. 43, no. 3, pp. 552–557, 2011.

[135] A. Aguzzi and L. Rajendran, “The transcellular spread of cytosolic amyloids, prions, and prionoids,” *Neuron*, vol. 64, no. 6, pp. 783–790, 2009.

[136] E. Angot, J. A. Steiner, C. Hansen, J. Y. Li, and P. Brundin, “Are synucleinopathies prion-like disorders?” *The Lancet Neurology*, vol. 9, no. 11, pp. 1128–1138, 2010.

[137] P. Brundin, R. Melki, and R. Kopito, “Prion-like transmission of protein aggregates in neurodegenerative diseases,” *Nature Reviews Molecular Cell Biology*, vol. 11, no. 4, pp. 301–307, 2010.

[138] M. Goedert, F. Clavaguera, and M. Tolnay, “The propagation of prion-like protein inclusions in neurodegenerative diseases,” *Trends in Neurosciences*, vol. 33, no. 7, pp. 317–325, 2010.
[139] R. Chia, M. H. Tattum, S. Jones, J. Collinge, E. M. C. Fisher, and G. S. Jackson, “Superoxide dismutase 1 and tgSOD1G93A mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis,” PLoS One, vol. 5, no. 5, Article ID e10627, 2010.

[140] C. Münch, J. O’Brien, and A. Bertolotti, “Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3548–3553, 2011.

[141] P. H. Ren, J. E. Lauckner, I. Kachirskaia, J. E. Heuser, R. Melki, and R. R. Kopito, “Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates,” Nature Cell Biology, vol. 11, no. 2, pp. 219–225, 2009.

[142] Y. Furukawa, K. Kaneko, S. Watanabe, K. Yamanaka, and N. Nukina, “A seeding reaction recapitulates intracellular formation of sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions,” The Journal of Biological Chemistry, vol. 286, no. 21, pp. 18664–18672, 2011.

[143] M. Novák, “Truncated tau protein as a new marker for Alzheimer’s disease,” Acta Virologica, vol. 38, no. 3, pp. 173–189, 1994.

[144] F. Clavaguera, T. Bolmont, R. A. Crowther et al., “Transmission and spreading of tauopathy in transgenic mouse brain,” Nature Cell Biology, vol. 11, no. 7, pp. 909–913, 2009.

[145] B. Frost, R. L. Jacks, and M. I. Diamond, “Propagation of Tau misfolding from the outside to the inside of a cell,” The Journal of Biological Chemistry, vol. 284, no. 19, pp. 12845–12852, 2009.

[146] B. Frost, J. Ollesch, H. Wille, and M. I. Diamond, “Conformational diversity of wild-type tau fibrils specified by templated conformation change,” The Journal of Biological Chemistry, vol. 284, no. 6, pp. 3546–3551, 2009.

[147] H. Braak and K. Del Tredici, “The pathological process underlying Alzheimer’s disease in individuals under thirty,” Acta Neuropathologica, vol. 121, no. 2, pp. 171–181, 2011.

[148] H. Braak and K. Del Tredici, “Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?” Acta Neuropathologica, vol. 121, no. 5, pp. 589–595, 2011.

[149] H. Braak and E. Braak, “Neuropathological stageing of Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no. 4, pp. 239–259, 1991.

[150] H. Braak, I. Alafuzoff, T. Arzberger, H. Kretzschmar, and K. Tredici, “Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry,” Acta Neuropathologica, vol. 112, no. 4, pp. 389–404, 2006.

[151] I. Alafuzoff, T. Arzberger, S. Al-Sarraj et al., “Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe consortium,” Brain Pathology, vol. 18, no. 4, pp. 484–496, 2008.

[152] W. E. Balch, R. I. Morimoto, A. Dillin, and J. W. Kelly, “Adapting proteostasis for disease intervention,” Science, vol. 319, no. 5865, pp. 916–919, 2008.

[153] M. Urushitani, A. Sik, T. Sakurai, N. Nukina, R. Takahashi, and J. P. Julien, “Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis,” Nature Neuroscience, vol. 9, no. 1, pp. 108–118, 2006.

[154] W. T. Hu, A. Chen-Plotkin, S. E. Arnold et al., “Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease,” Acta Neuropathologica, vol. 120, no. 3, pp. 385–399, 2010.

[155] B. Mollenhauer, M. Bibl, H. Esselmann et al., "CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia," Journal of Neural Transmission, vol. 114, no. 7, pp. 919–927, 2007.

[156] X. Hu, S. L. Crick, G. Bu, C. Frieden, R. V. Pappu, and J. M. Lee, “Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20324–20329, 2009.

[157] M. Bibl, B. Mollenhauer, H. Esselmann et al., “CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia,” Brain, vol. 129, no. 5, pp. 1177–1187, 2006.

[158] T. Tomiyama, S. Matsuyama, H. Iso et al., “A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo,” Journal of Neuroscience, vol. 30, no. 14, pp. 4845–4856, 2010.

[159] L. K. Clinton, M. Blurton-Jones, K. Myczek, J. Q. Trojanowski, and F. M. LaFerla, “Synergistic interactions between Aβ, tau, and α-synuclein: acceleration of neuropathology and cognitive decline,” Journal of Neuroscience, vol. 30, no. 21, pp. 7281–7289, 2010.
[160] R. E. Mrak and W. S. T. Griffin, “Common inflammatory mechanisms in Lewy body disease and Alzheimer disease,” *Journal of Neuropathology and Experimental Neurology*, vol. 66, no. 8, pp. 683–686, 2007.

[161] J. A. Fein, S. Sokolow, C. A. Miller et al., “Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes,” *American Journal of Pathology*, vol. 172, no. 6, pp. 1683–1692, 2008.

[162] R. H. Takahashi, E. Capetillo-Zarate, M. T. Lin, T. A. Milner, and G. K. Gouras, “Co-occurrence of Alzheimer’s disease β-amyloid and tau pathologies at synapses,” *Neurobiology of Aging*, vol. 31, no. 7, pp. 1145–1152, 2010.

---

**This article should be cited as follows:**

Kurt A. Jellinger, “Interaction between α-Synuclein and Other Proteins in Neurodegenerative Disorders,” *TheScientificWorldJournal*, vol. 11, pp. 1893–1907, 2011.